Paragon Capital Management Inc. Invests $602,000 in Moderna, Inc. (NASDAQ:MRNA)

Paragon Capital Management Inc. bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, Holdings Channel.com reports. The firm bought 5,070 shares of the company’s stock, valued at approximately $602,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC acquired a new stake in Moderna in the 2nd quarter valued at about $26,000. Cedar Wealth Management LLC increased its holdings in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in shares of Moderna in the first quarter valued at approximately $32,000. Family Firm Inc. purchased a new position in Moderna during the second quarter worth approximately $33,000. Finally, Rise Advisors LLC boosted its stake in Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Trading Down 1.2 %

Shares of MRNA stock opened at $63.16 on Thursday. The stock has a market capitalization of $24.21 billion, a P/E ratio of -4.03 and a beta of 1.67. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The company has a 50 day moving average price of $80.88 and a 200 day moving average price of $108.62.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same period last year, the firm earned ($3.62) earnings per share. Equities research analysts predict that Moderna, Inc. will post -9.86 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Bank of America cut their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. Barclays cut their price objective on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a research report on Monday, September 16th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and decreased their target price for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. JPMorgan Chase & Co. downgraded shares of Moderna from a “neutral” rating to an “underweight” rating and cut their price target for the stock from $88.00 to $70.00 in a report on Friday, September 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Moderna has a consensus rating of “Hold” and a consensus price target of $100.44.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the completion of the transaction, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Moderna news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00. Following the transaction, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. The disclosure for this sale can be found here. Insiders have sold 78,158 shares of company stock valued at $9,259,012 in the last quarter. Corporate insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.